ACTIVITY LINKS Activity Home Page Required Materials Accreditation Info Learning Objectives Instructions for Credit Faculty Disclosures Privacy Policy

Joint-Sponsorship Information:

This activity is jointly sponsored by Medical Education Collaborative, Inc. (MEC) and The Body PRO. For questions regarding the accreditation of this activity, please call MEC at (303) 420-3252.

For Physicians:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and The Body PRO. MEC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Collaborative designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For Nurses:

Medical Education Collaborative (MEC) is the accredited provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

RNs, LPNs, LVNs and NPs can receive up to 0.5 contact hours for participation in this program. This program is cosponsored with Medical Education Collaborative, Inc. (MEC) and The Body PRO. Provider approved by the California Board of Registered Nursing, Provider Number CEP 12990, for 0.6 contact hour(s).

Release Date: July 25, 2007. This activity is valid for credit through July 25, 2008.

Purpose Statement:

The purpose of this activity is to provide HIV physicians, nurses and other health care professionals with the opportunity to supplement their knowledge on issues related to the treatment of HIV-infected patients. This will be accomplished via a CME- and CE-accredited summary of highlighted research from the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

Target Audience:

This continuing-education activity has been developed for the educational benefit of physicians, nurses and other health care professionals involved in the clinical care of, or research efforts that impact the clinical care of, individuals with HIV.

Objectives:

Participants who complete this educational activity should be able to:

1. Explain the clinical significance of the latest results from the TITAN study comparing darunavir to lopinavir.
2. Assess the potential value of MK-0518 (raltegravir) as a therapy option for HIV treatment-naive patients, based on study results presented at IAS 2007.
3. Summarize the latest presented data regarding TMC278 (rilpivirine), particularly in regards to a possible interaction with H2 antagonists.
4. Show familiarity with newly presented data at IAS 2007 regarding CCR5 inhibitors in development.
5. Discuss the significance of a SMART substudy focusing on the impact of HIV treatment discontinuation on HIV/hepatitis-coinfected patients.
   

This activity is no longer available for CME/CE credit.